Literature DB >> 12556347

The melanocortin system.

Ira Gantz1, Tung M Fong.   

Abstract

The melanocortin system consists of melanocortin peptides derived from the proopiomelanocortin gene, five melanocortin receptors, two endogenous antagonists, and two ancillary proteins. This review provides an abbreviated account of the basic biochemistry, pharmacology, and physiology of the melanocortin system and highlights progress made in four areas. In particular, recent pharmacological and genetic studies have affirmed the role of melanocortins in pigmentation, inflammation, energy homeostasis, and sexual function. Development of selective agonists and antagonists is expected to further facilitate the investigation of these complex physiological functions and provide an experimental basis for new pharmacotherapies.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12556347     DOI： 10.1152/ajpendo.00434.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN： 0193-1849            Impact factor:   4.310


  112 in total

1.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

2.  Effects of macrocycle size and rigidity on melanocortin receptor-1 and -5 selectivity in cyclic lactam alpha-melanocyte-stimulating hormone analogs.

Authors:  Alexander V Mayorov; So-Yeop Han; Minying Cai; Matthew R Hammer; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

3.  Cell signaling and trafficking of human melanocortin receptors in real time using two-photon fluorescence and confocal laser microscopy: differentiation of agonists and antagonists.

Authors:  Minying Cai; Eva V Varga; Magda Stankova; Alexander Mayorov; Joseph W Perry; Henry I Yamamura; Dev Trivedi; Victor J Hruby
Journal:  Chem Biol Drug Des       Date:  2006-10       Impact factor: 2.817

4.  Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.

Authors:  Alexander V Mayorov; Minying Cai; Kevin B Chandler; Ravil R Petrov; April R Van Scoy; Zerui Yu; Dustin K Tanaka; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

5.  Semax corrects brain dysfunction caused by prenatal introduction of valproic acid.

Authors:  A V Malyshev; E V Razumkina; V A Dubynin; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2013-07-03

Review 6.  Intracellular signaling mechanisms of the melanocortin receptors: current state of the art.

Authors:  Adriana R Rodrigues; Henrique Almeida; Alexandra M Gouveia
Journal:  Cell Mol Life Sci       Date:  2014-12-12       Impact factor: 9.261

7.  Obesity-related genetic variants, human pigmentation, and risk of melanoma.

Authors:  Xin Li; Liming Liang; Mingfeng Zhang; Fengju Song; Hongmei Nan; Li-E Wang; Qingyi Wei; Jeffrey E Lee; Christopher I Amos; Abrar A Qureshi; Jiali Han
Journal:  Hum Genet       Date:  2013-03-29       Impact factor: 4.132

8.  Regions of melanocortin 2 (MC2) receptor accessory protein necessary for dual topology and MC2 receptor trafficking and signaling.

Authors:  Julien A Sebag; Patricia M Hinkle
Journal:  J Biol Chem       Date:  2008-11-03       Impact factor: 5.157

9.  Characterization of Japanese quail yellow as a genomic deletion upstream of the avian homolog of the mammalian ASIP (agouti) gene.

Authors:  Nicola J Nadeau; Francis Minvielle; Shin'ichi Ito; Miho Inoue-Murayama; David Gourichon; Sarah A Follett; Terry Burke; Nicholas I Mundy
Journal:  Genetics       Date:  2008-02       Impact factor: 4.562

10.  Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion.

Authors:  Giovanna Leoni; Hetal B Patel; André L F Sampaio; Felicity N E Gavins; Joanne F Murray; Paolo Grieco; Stephen J Getting; Mauro Perretti
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.